Cited by 3,014Dementia and Cognitive Impairment ResearchCancer-related cognitive impairment studiesAlzheimer's disease research and treatments

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Open access
Jessen, Frank, Amariglio, Rebecca E., van Boxtel, Martin, Breteler, Monique, Ceccaldi, Mathieu, Chételat, Gaël, Dubois, Bruno, Dufouil, Carole +29 more·2014·Alzheimer's & Dementia

Abstract

There is increasing evidence that subjective cognitive decline (SCD) in individuals with unimpaired performance on cognitive tests may represent the first symptomatic manifestation of Alzheimer's disease (AD). The research on SCD in early AD, however, is limited by the absence of common standards. The working group of the Subjective Cognitive Decline Initiative (SCD‐I) addressed this deficiency by reaching consensus on terminology and on a conceptual framework for research on SCD in AD. In this publication, research criteria for SCD in pre‐mild cognitive impairment (MCI) are presented. In addition, a list of core features proposed for reporting in SCD studies is provided, which will enable comparability of research across different settings. Finally, a set of features is presented, which in accordance with current knowledge, increases the likelihood of the presence of preclinical AD in individuals with SCD. This list is referred to as SCD plus .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.01.001

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SCD is postulated to manifest at a relatively late phase of preclinical AD.

    “SCD is postulated to manifest at a relatively late phase of preclinical AD and is associated with increased risks of AD biomarker abnormalities and future cognitive decline and dementia [2, 4, 6]”

    From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [4]

    Section 3 says SCD can occur during preclinical AD, and the Introduction discusses subjective decline as a possible indicator of early effects of AD pathology. The paper does not establish that SCD manifests specifically at a relatively late phase of preclinical AD; the Introduction also describes its potential value at a very early disease stage. Page numbers were not available in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • SCD is regarded as the first clinical manifestation in the AD continuum.

    “Subjective cognitive decline (SCD), the first clinical manifestation in the AD continuum, is self-experienced decline in cognitive function without evidence of objective cognitive impairment [3–5].”

    From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [4]

    The Introduction describes SCD as a possible indicator of the first effects of AD pathology on cognition, and section 3 says it may be a symptomatic indicator of preclinical AD. But the paper does not establish SCD as the first clinical manifestation in the AD continuum: section 3 says SCD is not present in every case of preclinical AD and can have causes other than AD. Page numbers are not available in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Subjective cognitive decline is one of the earliest warning signs of dementia and may be a way to identify people who are at high risk of developing Alzheimer's or other dementias, as well as MCI.

    “Subjective cognitive decline is one of the earliest warning signs of dementia and may be a way to identify people who are at high risk of developing Alzheimer's or other dementias, as well as MCI.”

    From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [274]

    The Introduction (page unavailable) describes subjective cognitive decline as potentially informative at a very early stage of Alzheimer’s disease and associates it with increased risk of future cognitive decline and Alzheimer’s dementia. It also places subjective decline before MCI, but does not establish that it identifies people at high risk of developing other dementias. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • For some people, subjective cognitive decline is normal aging, but for others, these symptoms can be a warning sign of future Alzheimer's disease.

    “For some people, this is normal aging, but for others, these symptoms can be a warning sign of future Alzheimer's disease.[246][247][248][249][250]”

    From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [248]

  • In 2014, the SCD-I proposed a consensus terminology and conceptual framework for research on SCD related to AD, including SCD-plus features.

    “In 2014, a consensus terminology and a conceptual framework for research on SCD related to AD was proposed by the Subjective Cognitive Decline Initiative (SCD-I) [4].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., Glodzik, L., van Harten, A. C., de Leon, M. J., McHugh, P., Mielke, M. M., Molinuevo, J. L., Mosconi, L., Osorio, R. S., Perrotin, A., Petersen, R. C., Rabin, L. A., Rami, L., Reisberg, B., Rentz, D. M., Sachdev, P. S., de la Sayette, V., Saykin, A. J., Scheltens, P., Shulman, M. B., Slavin, M. J., Sperling, R. A., Stewart, R., Uspenskaya, O., Vellas, B., Visser, P. J., Wagner, M., & Subjective Cognitive Decline Initiative (SCD‐I) Working Group
Affiliations
  • University of Bonn (DE)
  • Brigham and Women's Hospital (US)
  • Department of Psychiatry and Neuropsychology School for Mental Health and Neuroscience (MHeNS), Maastricht University Maastricht The Netherlands
  • German Center for Neurodegenerative Diseases (DE)
  • Institut de Neurosciences des Systèmes (FR)
  • Inserm (FR)
  • Université Pierre-et-Marie-Curie (FR)
  • Université de Bordeaux (FR)
  • The University of Melbourne (AU)
  • Alzheimer Center Department of Neurology, Neuroscience Campus Amsterdam VU University Medical Centre Amsterdam The Netherlands
  • NYU Langone Health (US)
  • Department of Psychiatry New York University Langone Medical Center New York NY USA
  • Mayo Clinic (US)
  • Alzheimer's Disease and Other Cognitive Disorders Unit IDIBAPS, Hospital Clinic Barcelona Spain
  • The Graduate Center, CUNY (US)
  • Hospital Clínic de Barcelona (ES)
  • UNSW Sydney (AU)
  • INSERM, U1077 Caen France
  • Indiana University School of Medicine (US)
  • Amsterdam Neuroscience (NL)
  • King's College London (GB)
  • Pitié-Salpêtrière Hospital (FR)
  • Université Toulouse III - Paul Sabatier (FR)
  • Maastricht University (NL)
Corresponding author
Jessen, Frank
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-05-02
Volume
10
Issue
6
Pages
844-852
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2048505725
Cited by
3,014
References
63
Citations by year
2026: 313 · 2025: 357 · 2024: 408 · 2023: 324 · 2022: 308 · 2021: 343 · 2020: 266 · 2019: 216 · 2018: 174 · 2017: 137 · 2016: 81 · 2015: 71 · 2014: 12
FWCI
13.81
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Research Portal (King's College London) (submittedVersion)
  • DZNE Pub (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • PMC
Funders
  • National Institutes of Health (UL1TR001108)
  • National Institute on Aging (P30AG010133, R01AG022374, P30AG008051, K23AG044431, R01AG019771)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
subjective cognitive decline, preclinical Alzheimer's disease
MeSH terms
Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Neuropsychological Tests, Terminology as Topic, Psychiatric Status Rating Scales, Age of Onset, Disease Progression, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review